该文研究了岩藻低聚糖的最佳酶解条件及对高尿酸血症小鼠的降尿酸效果。采用岩藻多糖酶（专利授权号ZL201210555581.6）降解岩藻多糖获得岩藻低聚糖，以黄嘌呤氧化酶抑制率为指标探究其最佳酶解条件，并用高尿酸血症小鼠模型探究其降尿酸效果。研究结果表明，最佳酶解温度为30 ℃，最佳酶解时间为1.5 h，最佳酶添加量为2 000 U/g，最佳多糖质量浓度为10 mg/mL；酶解后，重均分子量由7.873×105 u降至8.508×103 u；酶解产物用超滤膜进行分级后，小于5 ku的岩藻低聚糖对黄嘌呤氧化酶的抑制作用最强，抑制率为88.65%，硫酸根含量为30.93%，岩藻糖含量为33.16%，葡萄糖醛酸含量为9.29%；与模型组相比，小于5 ku的岩藻低聚糖能够增加小鼠体重，缓解建模药物对肝脏、肾脏和脾脏的损伤，显著降低小鼠血清肌酐、尿素氮的含量，150 mg/kg、300 mg/kg样品组小鼠血清尿酸值分别降低42.10%和25.63%，小鼠黄嘌呤氧化酶活性分别降低10.04%和8.57%，小鼠腺苷脱氨酶活性分别降低2.83%和5.25%。小于5 ku的岩藻低聚糖对高尿酸血症小鼠具有显著的降尿素效果。该研究为岩藻低聚糖的开发利用奠定了理论基础。

In this study, the optimal conditions for enzymatic hydrolysis of fucoidan oligosaccharides and their uric acid-lowering effect in mice with hyperuricemia were investigated. Fucoidanase (Patent Grant No.ZL201210555581.6) was used to break down fucoidan to obtain fucoidan oligosaccharides, and the optimal enzymatic hydrolysis conditions were explored by taking the inhibition rate of xanthine oxidase as the index. The uric acid-lowering effect was examined by using a hyperuricemia mouse model. The results showed that the optimum enzymatic hydrolysis temperature was 30 ℃ , the optimum enzymatic digestion time was 1.5 h, the optimum enzyme dosage was 2 000 U/g, and the optimum polysaccharide mass concentration was 10 mg/mL. After the enzymatic hydrolysis, the average molecular weight decreased from 7.873×105 u to 8.508×103 u; After the enzymatic hydrolysate was fractionated with an ultrafiltration membrane, the fucoidan oligosaccharides less than 5 ku had the strongest inhibitory effect against xanthine oxidase, with the inhibition rate as 88.65%, sulfate content as 30.93%, fucose content as 33.16%, and glucuronic acid content as 9.29%; Compared with the model group, fucoidan oligosaccharides less than 5 ku could increase the body weights of mice and alleviate the damage to the liver, kidney, and spleen caused by the model drug, and significantly reduce the serum creatinine and urea nitrogen levels of mice. In mice, the treatment with 150 mg/kg and 300 mg/kg fucoidan oligosaccharides decreased the serum uric acid value by 42.10% and 25.63%, respectively, the xanthine oxidase activity by 10.04% and 8.57%, respectively, and the adenosine deaminase activity by 2.83% and 5.25%, respectively. The fucoidan oligosaccharidess less than 5 ku had a significant uric acic-lowering effect in mice with hyperuricemia. This study has laid a theoretical foundation for the development and utilization of fucoidan oligosaccharidess.

山东省青年科学基金资助项目（662/2321613）；横向技术开发项目（20223702030327）